New drug combo shows promise in Hard-to-Treat cancers
NCT ID NCT02498613
First seen Oct 31, 2025 · Last updated Jun 17, 2026 · Updated 36 times
Summary
This study tests a combination of two drugs, cediranib and olaparib, in people with advanced solid tumors that have spread or cannot be removed by surgery. The cancers include certain types of breast, lung, and pancreatic cancer. The goal is to see if the combination can shrink tumors or slow their growth by blocking enzymes that cancer cells need to grow and by cutting off the tumor's blood supply.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
BCCA-Vancouver Cancer Centre
Vancouver, British Columbia, V5Z 4E6, Canada
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Moffitt Cancer Center-International Plaza
Tampa, Florida, 33607, United States
-
Smilow Cancer Center/Yale-New Haven Hospital
New Haven, Connecticut, 06510, United States
-
UC San Diego Medical Center - Hillcrest
San Diego, California, 92103, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
UCSF Medical Center-Mount Zion
San Francisco, California, 94115, United States
-
University Health Network-Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
VCU Massey Comprehensive Cancer Center
Richmond, Virginia, 23298, United States
-
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, 37232, United States
-
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Weisberg Cancer Treatment Center
Farmington Hills, Michigan, 48334, United States
-
Yale University
New Haven, Connecticut, 06520, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.